A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis

Revmatologiia

Volumn 40, Issue 12, 2001, Pages 1359-1364

  McGarry, F ^a   Neilly, J ^a   Anderson, N ^b   Sturrock, R ^a   Field, M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Ankylosing spondylitis; Genetics; Interleukin 1; Restriction fragment length polymorphism; Variable number tandem repeat

Indexed keywords

CYTOKINE; DNA; HLA B27 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ADOLESCENT; ADULT; AGED; ALLELE; ANKYLOSING SPONDYLITIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC PREDISPOSITION; GENETIC REGULATION; HEREDITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SACROILIITIS; STATISTICAL PARAMETERS; TANDEM REPEAT; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ALLELES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; MINISATELLITE REPEATS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SIALOGLYCOPROTEINS; SPONDYLITIS, ANKYLOSING;

EID: 0035684706     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DCO, Sturrock RD. Ankylosing spondylitis and HLA 27. Lancet 1973;1:904-7.
2. Brown MA, Pile KD, Kennedy LG et al. A genome wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998;41:588-95.
3. Brown MA, Kennedy LG, MacGregor HA et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA and the environment. Arthritis Rheum 1997;40:1823-8.
4. Braun J, Bollow M, Neure I et al. Use of immunohistologic and in-situ hybridisation techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499-505.
5. Van der Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB. Role of interleukin-1, tumour necrosis factor alpha and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen and zymosan induced arthritis. Arthritis Rheum 1995;38:164-72.
6. Collotta F, Rae F, Muzio M et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
7. Jiang Y, Genant HK, Watt I et al. A multicentre, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologie progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
8. Dale M, Nicklin MJH. Interleukin-1 receptor cluster: Gene organisation of IL1R2, IL1R1, IL1RL2 (IL-14rp2), IL1RL1 (T1/ST2) and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 1999;57:177-9.
9. Danis VA, Millington M, Hyland V, Grennan D. Cytokine production by normal human monocytes - inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1RA) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
10. Blakemore AIF, Cox A, Gonzalez AM et al. Interleukin-1 receptor antagonist allele (IL-1RN(*)2) associated with nephropathy in diabetes mellitus. Hum Genet 1996;97:369-74.
11. Tjernstrom F, Hellmer G. Nived O, Truedsson L, Sturfelt G. Synergistic effect between interleukin-1 receptor antagonist allele (IL-1RN*2) and MHC Class II (DR17, DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 1999;8:103-8.
12. Mansfield JC, Holden H, Tarlow JK et al. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106:637-42.
13. Carter MJ, Duff GW, Lobo AJ, DiGiovine FS. Association of interleukin-1-receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001;48:461-7.
14. Haker UT, Gomololka M, Keller E et al. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut 1997;40:623-7.
15. McDowell TL, Symonds JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995;38:221-8.
16. Donn RP, Farhan AJ, Barren JH, Thomson W, Worthington J, Ollier WE. Absence of association between interleukin 1 alpha and oligoarticular juvenile chronic arthritis in UK patients. Rheumatology 1999;38:171-5.
17. Bennett PH, Wood PH (eds). Population studies of rheumatic diseases. Exc Med Found Amsterdam Int Congr Ser No. 148:456.
18. McGarry F, Walker R, Sturrock RD, Field M. The - 308.1 polymorphism in the promoter region of the tumour necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol 1999;26:1110-6.
19. Sham PC, Curtis D. Monte-Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;25:97-105.
20. Van der Paardt M, van der Horst-Bruinsma IE, Crusius JB et al. Interleukin-1 beta (IL-1β) and interleukin 1 receptor antagonist (IL-1Ra) gene polymorphisms in the susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000;59(Suppl. 1):117.
21. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998;28:2598-602.
22. Crilly A, Maiden N, Capell H, Madhok R. The predictive value of interleukin 1 gene polymorphisms for surgery. Ann Rheum Dis 2000;59:695-9.
23. Javosava K, Nemcova D, Ruzickova S et al. Interleukin 1 receptor antagonist gene allele 2 increased in patients with juvenile idiopathic arthritis. Ann Rheum Dis 2000; 59(Suppl. 1):253.
24. Genebank: http://www.ncbi/mlm/nih.gov/genemap/map, cgi?CHR=2
25. Carter MJ, Duff GW, Lobo AJ, diGiovine FS. Allele-specific mRNA assessment in colonic mucosa in ulcerative colitis: Association of the interleukin-receptor antagonist gene allele 2 with reduced steady state mRNA levels. Gastroenterology 1999;116:G2952.
26. Hohler T, Schaper T, Schneider PM, Meyer zum Buschenfelde K-H, Marker-Hermann E. Association of different tumour necrosis factor a promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1998;41:1489-92.
27. Verjans GMGM, Brinkman BMN, Van Doornik CEM, Kijilstra A, Verweij CL. Polymorphisms of tumour necrosis factor-alpha (TNF-α) at position - 308 in relation to ankylosing spondylitis. Clin Exp Immunol 1994; 97:45-7.
28. Milicic A, Lindheimer F, Laval S et al. Interethnic studies of tumour necrosis factor polymorphisms confirm the likelihood of a second MHC susceptibility locus in ankylosing spondylitis. Genes Immun 2000; 1:418-22.
29. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumour necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
30. Braun J, Yin Z, Spiller I et al. Low secretion of tumour necrosis factor α, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999; 42:2039-44.
31. Maeda S, Kokubun S. Changes with age in proteoglycan synthesis in cell cultures in vitro from the inner and outer rabbit annulus fibrosus. Responses to interleukin-1 and interleukin-1 receptor antagonist. Spine 2000; 25:166-9.
32. Mehrian R, Quismorio FP, Strassmann G et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41:596-602.